Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments

HJC de Vries, HD Schallig - American journal of clinical dermatology, 2022‏ - Springer
This review is an update of an earlier narrative review published in 2015 on developments
in the clinical management of cutaneous leishmaniasis (CL) including diagnosis, treatment …

Cutaneous leishmaniasis: recent developments in diagnosis and management

HJC de Vries, SH Reedijk, HDFH Schallig - American journal of clinical …, 2015‏ - Springer
This review focuses on recent developments in the diagnosis, treatment, management, and
strategies for the prevention and control of cutaneous leishmaniasis (CL) caused by both …

Leishmaniasis drug discovery: recent progress and challenges in assay development

B Zulfiqar, TB Shelper, VM Avery - Drug discovery today, 2017‏ - Elsevier
Highlights•Leishmaniasis remains a neglected tropical disease, with a high unmet medical
need.•Therapeutic efficacy varies depending on the species of Leishmania parasite.•Leads …

Leishmania RNA virus: when the host pays the toll

MA Hartley, C Ronet, H Zangger… - Frontiers in cellular …, 2012‏ - frontiersin.org
The presence of an RNA virus in a South American subgenus of the Leishmania parasite,
L.(Viannia), was detected several decades ago but its role in leishmanial virulence and …

Species ty** in dermal leishmaniasis

G Van der Auwera, JC Dujardin - Clinical microbiology reviews, 2015‏ - journals.asm.org
Leishmania is an infectious protozoan parasite related to African and American
trypanosomes. All Leishmania species that are pathogenic to humans can cause dermal …

New approaches from nanomedicine for treating leishmaniasis

V Gutiérrez, AB Seabra, RM Reguera… - Chemical Society …, 2016‏ - pubs.rsc.org
Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa,
threatens 350 million people in 98 countries around the world. There are already 12 million …

Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse

E Bourreau, M Ginouves, G Prévot… - The Journal of …, 2016‏ - academic.oup.com
Abstract Treatment failure and symptomatic relapse are major concerns in American
tegumentary leishmaniasis (TL). Such complications are seen frequently in Leishmania …

Development and validation of PCR-based assays for diagnosis of American cutaneous leishmaniasis and identificatio nof the parasite species

GC Graça, AC Volpini, GAS Romero… - Memórias do Instituto …, 2012‏ - SciELO Brasil
In this study, PCR assays targeting different Leishmania heat-shock protein 70 gene (hsp70)
regions, producing fragments ranging in size from 230-390 bp were developed and …

Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update

L Reveiz, ANS Maia-Elkhoury, RS Nicholls… - PloS one, 2013‏ - journals.plos.org
Introduction Leishmaniasis is an important public health problem in the Americas. A
Cochrane review published in 2009 analyzed 38 randomized controlled trials (RCT). We …

Application of dendrimers for the treatment of infectious diseases

Z Mhlwatika, BA Aderibigbe - Molecules, 2018‏ - mdpi.com
Dendrimers are drug delivery systems that are characterized by a three-dimensional, star-
shaped, branched macromolecular network. They possess ideal properties such as low …